Literature DB >> 22492522

Clinical and pathological improvement in stroke-prone spontaneous hypertensive rats related to the pleiotropic effect of cilostazol.

Yoshio Omote1, Kentaro Deguchi, FengFeng Tian, Hiromi Kawai, Tomoko Kurata, Toru Yamashita, Yasuyuki Ohta, Koji Abe.   

Abstract

BACKGROUND AND
PURPOSE: Cerebral infarction is a major cause of death or decreasing activities of daily living. This study aimed to investigate the efficacy of commonly used antiplatelet drugs on stroke and motor and cognitive functions in relation to oxidative stress markers and insulin-like growth factor 1 receptor (IGF-1R).
METHODS: Stroke-prone spontaneously hypertensive rats were treated with vehicle, aspirin, clopidogrel, and cilostazol from 8 to 10 weeks of age. Physiological parameters, regional cerebral blood flow, and serum lipids were examined. Motor and cognitive functions were evaluated weekly by the Rotorod and water maze task. Spontaneous infarct volume, oxidative stress markers for lipid, protein, and DNA at the ischemic boundary zone of spontaneous infarction, and the IGF-1R-positive cell ratio in the hippocampus were immunohistochemically examined in brain sections. IGF-1Rβ expression in the hippocampus was assessed by Western blotting.
RESULTS: The antiplatelet drugs, cilostazol and clopidogrel, reduced the spontaneous infarct volume more than aspirin. Only cilostazol improved motor and cognitive functions with a significant increase (P<0.05) in the memory-related IGF-1R-positive ratio and IGF-1Rβ expression in the hippocampus. Cilostazol reduced the 4 oxidative stress markers in affected neurons in stroke-prone spontaneously hypertensive rats regardless of blood pressure, regional cerebral blood flow, or serum lipid levels.
CONCLUSIONS: The present results suggest that a possible pleiotropic effect of cilostazol resulted in the reduction of spontaneous infarct volume and preservation of motor and spatial cognitive functions. The increase of IGF-1R-positive cells in the hippocampal CA1 region could partly explain the preservation of spatial cognitive function in stroke-prone spontaneously hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492522     DOI: 10.1161/STROKEAHA.111.643098

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

Review 1.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

2.  Neuroprotective effect of a new synthetic aspirin-decursinol adduct in experimental animal models of ischemic stroke.

Authors:  Bing Chun Yan; Joon Ha Park; Bich Na Shin; Ji Hyeon Ahn; In Hye Kim; Jae-Chul Lee; Ki-Yeon Yoo; In Koo Hwang; Jung Hoon Choi; Jeong Ho Park; Yun Lyul Lee; Hong-Won Suh; Jong-Gab Jun; Young-Guen Kwon; Young-Myeong Kim; Seung-Hae Kwon; Song Her; Jin Su Kim; Byung-Hwa Hyun; Chul-Kyu Kim; Jun Hwi Cho; Choong Hyun Lee; Moo-Ho Won
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 3.  Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions.

Authors:  Philip M Bath; Joanna M Wardlaw
Journal:  Int J Stroke       Date:  2015-03-02       Impact factor: 5.266

4.  Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset.

Authors:  Junya Aoki; Yasuyuki Iguchi; Takao Urabe; Hiroshi Yamagami; Kenichi Todo; Shigeru Fujimoto; Koji Idomari; Nobuyuki Kaneko; Takeshi Iwanaga; Tadashi Terasaki; Ryota Tanaka; Nobuaki Yamamoto; Akira Tsujino; Koichi Nomura; Koji Abe; Masaaki Uno; Yasushi Okada; Hideki Matsuoka; Sen Yamagata; Yasumasa Yamamoto; Toshiro Yonehara; Takeshi Inoue; Yoshiki Yagita; Kazumi Kimura
Journal:  J Am Heart Assoc       Date:  2019-07-26       Impact factor: 5.501

5.  Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial.

Authors:  Gordon W Blair; Jason P Appleton; Katie Flaherty; Fergus Doubal; Nikola Sprigg; Richard Dooley; Carla Richardson; Iona Hamilton; Zhe Kang Law; Yulu Shi; Michael S Stringer; Michael J Thrippleton; Julia Boyd; Kirsten Shuler; Philip M Bath; Joanna M Wardlaw
Journal:  EClinicalMedicine       Date:  2019-04-24

Review 6.  Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.

Authors:  Muzaimi Mustapha; Che Mohd Nasril Che Mohd Nassir; Niferiti Aminuddin; Amanina Ahmad Safri; Mazira Mohamad Ghazali
Journal:  Front Physiol       Date:  2019-10-24       Impact factor: 4.566

Review 7.  William M. Feinberg Award for Excellence in Clinical Stroke: Small Vessel Disease; a Big Problem, But Fixable.

Authors:  Joanna M Wardlaw
Journal:  Stroke       Date:  2018-06-12       Impact factor: 7.914

8.  Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study.

Authors:  Woo-Keun Seo; Jae-Young Kim; Eun-Hyeok Choi; Ye-Sel Kim; Jong-Won Chung; Jeffrey L Saver; Oh Young Bang; Gyeong-Moon Kim
Journal:  J Am Heart Assoc       Date:  2021-02-22       Impact factor: 5.501

9.  Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.

Authors:  Yoichi Ohnuki; Yuko Ohnuki; Saori Kohara; Mie Shimizu; Shunya Takizawa
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

10.  Antiplatelet and Antithrombotic Effects of Isaridin E Isolated from the Marine-Derived Fungus via Downregulating the PI3K/Akt Signaling Pathway.

Authors:  Ni Pan; Zi-Cheng Li; Zhi-Hong Li; Sen-Hua Chen; Ming-Hua Jiang; Han-Yan Yang; Yao-Sheng Liu; Rui Hu; Yu-Wei Zeng; Le-Hui Dai; Lan Liu; Guan-Lei Wang
Journal:  Mar Drugs       Date:  2021-12-24       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.